top of page


banner v right blue.png
Pancreatic VTS Cancer.png

Pancreatic Summits

Diagnosis and treatment of pancreatic cancer has a significant physical and emotional impact on patients and their loved ones.


The Victorian Tumour Summits are clinician-led forums seeking to identify unwarranted variations in tumour based clinical practice and cancer outcomes that could be addressed through state-wide action.


Seventy stakeholders from across Victoria gathered on November 24, 2017 to discuss variations in care and identify opportunities for improvement.

Pancreatic Cancer 2017 Clinical Working Party

  • Dr Rob Blum

  • Prof Christopher Christophi

  • Mr Dan Croagh

  • Mr David Deutscher

  • Mr Adrian Fox

  • A/Prof Peter Gibbs

  • Mr George Kalogeropoulos

  • Dr Richard Khor

  • A/Prof Brian Le

  • Dr Belinda Lee

  • Mr Mehrdad Nikfarjam

  • Mr Charles Pilgrim (Chair)

  • Dr Babak Tamjid

  • A/Prof Niall Tebbutt

  • A/Prof Ben Thomson

  • A/Prof Valery Usatoff

  • Prof John Zalcberg

Pancreatic Cancer 2017 Summit Material

Pancreatic Summit Material 2017
Pancreatic 2017 Summit Introduction Presentation

Prof. Robert Thomas

Pancreatic 2017 Summit Policy Context Presentation

Presented by Kathryn Whitfield

Pancreatic Cancer 2017 Summit Data Presentation

Presented by Dr Charles Pilgrim

Data Variations

Pancreatic 2017 Summit Clinical Working Party Chair Dr Charles Pilgrim presented on the variations in statewide data: 

  • One-year relative survival increased from 27% to 34% between 2011-15.

  • Post-operative mortality is low by international standards: 2.1% (30 days); 2.7% (90 days); 19.7% (1-year).

  • A decrease in the number of Victorian hospitals conducting low volumes of pancreatic resections (1-3 per year) from 10 to 4 between the 2014/15 and 2016/17 financial years.

  • Only 5% of patients who had curative surgery for non-metastatic pancreatic ductal adenocarcinoma had neoadjuvant therapy.

  • 23% of patients who had curative surgery for non-metastatic pancreatic ductal adenocarcinoma did not have adjuvant therapy.

Pancreatic Cancer 2017 Summit End of Day Presentation

Consumer Perspective: Pancreatic Cancer

bottom of page